Peptide Research Basics

The arbitrary cutoff between “peptide” and “protein” is around 50 amino acids, though it varies by convention. Insulin (51 amino acids) is usually classified as a protein; the GLP-1 receptor agonists ( semaglutide ~31 residues, tirzepatide ~39 residues) are firmly in peptide territory. What separates peptides from proteins functionally is structural complexity — peptides typically lack the elaborate folded tertiary structure that defines a protein.

1. GH-axis secretagogues. Stimulate endogenous growth hormone release. Ipamorelin, CJC-1295, Sermorelin are the most-studied examples.
2. GLP-class metabolic peptides. Incretin-receptor agonists for weight loss and glycemic control. Semaglutide, Tirzepatide, Retatrutide are the canonical mono-, dual-, and triple-agonist examples.
3. Healing and repair peptides. Tissue-recovery and anti-inflammatory effects. BPC-157, TB-500, and copper peptides like GHK-Cu are the headline compounds.
4. Cognitive peptides. Neurotrophic and cognitive-modulating compounds. Semax, Selank are the most-referenced.

Research interest has expanded sharply over the last decade because peptides occupy a useful design space — specific enough to target one receptor system cleanly, but small enough to manufacture synthetically at scale. The success of the GLP-1 class as a weight-loss therapy is the highest-profile example, but the broader research literature spans dozens of compounds across these categories.

1. Binding. The peptide docks into a receptor’s binding pocket via a precise shape match. Different peptides bind different receptors; small changes in peptide sequence can dramatically change which receptor it binds.
2. Conformational change. Binding mechanically deforms the receptor, exposing or activating sites on its intracellular side.
3. Cascade activation. The activated receptor triggers second-messenger systems (cAMP, IP3, calcium release) which in turn activate dozens of downstream enzymes and transcription factors.
4. Amplification. Each step in the cascade multiplies the signal. A single hormone-receptor interaction can ultimately cause the synthesis of thousands of new protein molecules inside the cell.

Why this matters for dosing. Because of cascade amplification, peptides produce systemic, measurable effects at nanogram-to-microgram quantities — orders of magnitude smaller than traditional small-molecule drugs, which usually have to occupy receptors in bulk (or block enzymes directly) and therefore need milligram-to-gram doses. A typical ibuprofen dose is 400 mg; a typical Ipamorelin dose is 200–300 mcg — roughly 2,000 times less mass, achieving its effect through receptor-mediated amplification rather than mass-action chemistry.

1. Receptor affinity. Peptides typically have sub-nanomolar binding affinities for their target receptors, meaning very small concentrations saturate receptor occupancy.
2. Endogenous reference. Endocrinology reference literature commonly cites native growth hormone as circulating in the low-single-digit-to-low-double-digit ng/mL range, and native GLP-1 in the low-double-digit pg/mL range between meals — figures Prof. Peptide has not traced to a single primary source for this page. Externally administered peptide doses are generally reported as calibrated to produce comparable plasma levels, not to greatly exceed them.
3. Signaling amplification. One receptor binding event triggers a downstream cascade that can produce thousands of protein-synthesis or enzyme-activation events — covered in the prior section. A microgram-scale dose is biochemically equivalent to a much larger dose of a non-amplifying compound.
4. Practical implication. Compound-specific dosing guides on this site report GH-axis and healing-peptide research doses in the low-hundred-microgram range and GLP-1-class doses in the single-digit milligram range weekly — both small in absolute terms compared to a typical small-molecule drug. Small-volume measurement tools matter as a result — a 0.3 or 0.5 mL insulin syringe is standard for peptide work, since 2–10 unit draws need to land cleanly on a tick mark.

The practical dose math — how a 10 mg vial reconstituted to a given volume yields a specific mcg-per-unit conversion — lives in the syringes and injection technique guide.

1. mg (milligram). 1/1,000 of a gram. Vial sizes are usually labelled in mg (5 mg, 10 mg, 15 mg).
2. mcg (microgram). 1/1,000 of a milligram, 1/1,000,000 of a gram. Most peptide doses are in mcg.
3. IU (International Unit). An activity-based unit, defined per-compound by the WHO. The conversion between IU and mg is compound-specific — there is no universal “X mg = Y IU” rule. HCG, HGH, and insulin are the peptides most commonly dosed in IU.

Why this matters. Misreading mg as mcg (or vice versa) is a 1,000× dosing error — a discrepancy large enough that a dose implausible for the compound is commonly reported as a sign the unit, not the number, is the error. Checking the unit on the vial label against the unit used in a protocol or dose calculation is a widely reported practice for catching this specific mistake before it happens.

1. Bacteriostatic water (BAC water). Sterile water + 0.9% benzyl alcohol. Supports multi-puncture vials for up to 28 days when refrigerated. The default for peptide reconstitution.
2. Sterile water for injection (SWFI). Sterile water with no preservative. Single-use only — once the vial is punctured, anything not immediately injected must be discarded.
3. Why BAC water is standard. Peptide vials are typically reconstituted once and drawn from repeatedly across a weeks-long protocol. SWFI would force discarding the entire vial after a single draw, which is wasteful and impractical for compounds dosed several times per week.
4. Exceptions. A small number of peptides are reported as incompatible with benzyl alcohol; manufacturers specify SWFI in the product literature for those. BAC water is reported as the default for peptide reconstitution generally, with a specific peptide’s own documentation taking precedence where it states otherwise.

For the actual reconstitution math — how the chosen water volume determines mcg-per-unit on the syringe — see the syringes and injection technique guide.

1. Lyophilized (powder) storage. Room temperature acceptable for short periods; refrigerated (2–8°C) for long-term. Most lyophilized peptides remain stable for 2+ years refrigerated, longer frozen.
2. Reconstituted (liquid) storage. Refrigerate at 2–8°C. Use within ~28 days — the in-use shelf life that benzyl alcohol’s bacteriostatic activity supports.
3. Freezing reconstituted peptides. Generally avoided for short-acting peptides — freeze-thaw cycles mechanically disrupt peptide structure and degrade activity. Acceptable for some long-acting peptides (the GLP-1 class tolerates a single freeze well) for extended storage beyond the 28-day in-use window.
4. Light exposure. Most peptides are light-sensitive in solution. Vendors ship in opaque or amber vials for this reason, and storing the vial in its original container is reported as standard practice; extended exposure to direct light on a counter is commonly reported as best avoided.
5. Temperature shocks. Repeated warming and cooling is reported to accelerate degradation more than a steady mid-range temperature would, which is why moving a vial directly between the fridge and the draw site, rather than leaving it out for extended periods, is commonly reported practice.
6. Visual inspection. A properly reconstituted peptide solution is clear and colorless. Cloudiness, particulates, or color change indicates degradation or contamination — discard the vial.

Receptor desensitization (tachyphylaxis). When a receptor is stimulated continuously, the cell often responds by reducing receptor surface expression, uncoupling the receptor from its downstream signaling machinery, or both. The end result is that the same external dose produces a smaller physiological effect over time. A washout period lets receptor expression and coupling return to baseline.

1. GH-axis secretagogues (Ipamorelin, CJC-1295, Sermorelin). Often researched in 5-on/2-off or 8-on/4-off patterns. The ghrelin and GHRH receptors desensitize meaningfully with continuous use, so periodic washouts are standard.
2. GLP-1 class metabolic peptides (Semaglutide, Tirzepatide, Retatrutide). Continuous weekly dosing is the standard in published Phase 3 trials. Receptor desensitization at therapeutic doses is less of an issue than in the GH-axis class, and trial protocols run multi-year continuous administration without scheduled washouts.
3. Healing and repair peptides (BPC-157, TB-500). Typically researched in 4–6 week active protocols followed by an off period of similar length. The cycle structure here is less about receptor desensitization (mechanism is incompletely characterized) and more about matching the duration of tissue-repair use cases.
4. Why patterns vary. Cycling is receptor-biology-driven, not a universal rule. The reported pattern depends on the specific receptor system, the peptide’s half-life, and the goal of the protocol — the cycling pattern reported in a given peptide’s own published research literature, where one exists, is the sourced figure for that compound.

1. HPLC (High-Performance Liquid Chromatography). Separates the contents of a sample into individual components by chemical behavior, then quantifies each. Reports the percentage of the named peptide vs everything else — the purity figure (e.g. “99.2%”).
2. Mass spectrometry. Measures the exact molecular weight of the dominant component. Confirms that the molecule present matches the expected structure of the named peptide. Catches mislabeling, substitution, and synthesis errors that HPLC alone might miss.
3. Certificate of Analysis (COA). The document summarizing test results for a specific batch — including peptide identity, purity, water content, sometimes endotoxin and microbial limits. A reputable vendor publishes the COA for each batch and ties it to a lot number on the vial.
4. What ≥99% purity means. 99% or more of the dry mass in the vial is the named peptide. The remaining 1% is typically synthesis byproducts, residual solvents, or trace water. Most research peptides target 98–99% as the practical floor; pharmaceutical-grade typically exceeds 99%.
5. Independent lab vs in-house testing. Independent labs — Janoshik Analytical, Colmaric Analyticals, and a handful of others — provide third-party verification: the lab is not the vendor, has no commercial incentive to inflate results, and signs the COA in its own name. In-house testing is performed by the vendor themselves; it’s informative but carries the conflict of interest.
6. Why publicly accessible COAs matter. A vendor that posts COAs publicly — with batch numbers traceable to the vial in hand — allows researchers to verify quality before purchase and audit it after. A vendor that claims testing without publishing the documents is asking for trust without offering verification.

1. Hands-on dose math and injection mechanics. Insulin syringes and injection technique — reading insulin syringes, choosing barrel sizes, converting units to mcg, subcutaneous technique, and site rotation.
2. Compound-specific research profiles. Most-referenced profiles for protocol context: Retatrutide, Semaglutide, Tirzepatide, BPC-157, Ipamorelin, CJC-1295.
3. Vendor codes. Verified discount codes from vetted research peptide vendors with current pricing references.